Five-year OLYMPUS data show Jelmyto (UGN-101) sustains kidney-sparing control in low-grade UTUC, with most responders ...

The IMpactMF trial was discontinued after an independent committee determined imetelstat was unlikely to improve overall ...

Zev A. Wainberg, MD, MSc, reviews RASolute 302 findings on daraxonrasib's OS benefit across RAS genotypes in metastatic pancreatic cancer.

COA urges Supreme Court review of Mississippi 340B contract pharmacy law, spotlighting PBM influence, drug access concerns, and calls for tighter oversight.

Bhavana Pothuri, MD, discusses TroFuse-005 at ESMO 2026, including TROP2 expression, treatment sequencing, and the future of ...

ADCs improved on chemotherapy-based regimens in PD-L1–negative and EGFR-mutated NSCLC, while chemotherapy plus pembrolizumab ...

Bhavana Pothuri, MD, discusses phase 3 TroFuse-005 data from ESMO, where sac-TMT improved PFS and OS vs chemotherapy in endometrial cancer.

Paul L. Swiecicki, MD, of the University of Michigan Rogel Cancer Center, addresses whether biomarker testing is needed to ...

Five phase 3 analyses presented as late-breaking abstracts at the 2026 European Society for Medical Oncology (ESMO) Congress ...

Torvu-Sam is moving into phase 3 trials at a dose of 2 mg/kg. In PROC, it will be compared with mirvetuximab soravtansine in ...

ESMO 2026 Presidential Symposium II recap: survival benefits reported across phase 3 Krascendo 1, SAFFRON, CLARITY-Gastric01, ...

Jacob Sands, MD, discusses the top findings from the phase 3 DeLLphi-305 study evaluating tarlatamab and durvalumab as ...